ORPHA:910
Xeroderma pigmentosum
Publications
15,929
97.6th percentile
Trials
6
Interventional, condition-specific
Researchers
1,139
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Xeroderma pigmentosum (XP) is a rare genodermatosis characterized by extreme sensitivity to ultraviolet (UV)-induced changes in the skin and eyes, and multiple skin cancers. It is subdivided into 8 complementation groups, according to the affected gene: classical XP (XPA to XPG) and XP variant (XPV).
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019600
- MeSH:D014983
- UMLS:C0043346
- NCIT:C3452
Additional Mondo synonyms (9)
Kaposi dermatosis · Kaposi disease · XP · angioma pigmentosum atrophicum · atrophoderma pigmentosum · melanosis lenticularis progressiva · pigmented epitheliomatosis · xeroderma of Kaposi · xeroderma pigmentosum syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
15,929 matched papers (5,256 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
6 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
15,929
15,929 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
15,929 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5,256 in the last 10 years · medium confidence · 97.6th percentile (publications denominator)
Phrase hits: 15,929 · MeSH hits: 0
Who's working on it?
1,139
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fassihi H8 papers · 2026
National Xeroderma Pigmentosum Service, St John's Institute of Dermatology, Guy's and St Thomas' Foundation Trust, London SE1 7EH, UK.
Papers in Europe PMC - 02Lehmann AR5 papers · 2026
National Xeroderma Pigmentosum Service, Department of Photodermatology, St John's Institute of Dermatology, and.
Papers in Europe PMC - 03Nishigori C5 papers · 2026
Department of Dermatology, Kobe University School of Medicine, Kobe, Japan.
Papers in Europe PMC - 04Fawcett H4 papers · 2026
Genome Damage and Stability Centre, University of Sussex, Brighton, UK.
Papers in Europe PMC - 05Gupta S4 papers · 2026
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
Papers in Europe PMC - 06Sarkany R4 papers · 2026
National Xeroderma Pigmentosum Service, St John's Institute of Dermatology, Guy's and St Thomas' Foundation Trust, London SE1 7EH, UK.
Papers in Europe PMC - 07Wang Q4 papers · 2026
Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Papers in Europe PMC - 08Ahuja R3 papers · 2025
Department of Dermatology and Venereology, AIIMS, New Delhi, India.
Papers in Europe PMC - 09Bertolotti A3 papers · 2026
CHU Reunion Island, CIC INSERM1410, Saint-Pierre, Reunion Island; CHU Reunion Island, Infectious Diseases - Dermatology Department, Saint-Pierre, Reunion Island, France.
Papers in Europe PMC - 10Bhari N3 papers · 2025
Department of Dermatology and Venereology, AIIMS, New Delhi, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; none in our sample are currently recruiting.
Data as of 27 July 2026
6 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89th percentile).
medium confidence · 89th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06330324·ENROLLING BY INVITATION·Reproductive Options in Inherited Skin Diseases
Conditions: Ichthyosis · Palmoplantar Keratoses · Epidermolysis Bullosa · Ectodermal Dysplasia·Matched via name phrase
- NCT05484570·RECRUITING·Natural History Study for DNA Repair Disorders
Conditions: DNA Repair Disorder · Cockayne Syndrome · Xeroderma Pigmentosum · Trichothiodystrophy·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Xeroderma pigmentosum" OR "Kaposi dermatosis" OR "Kaposi disease" OR "angioma pigmentosum atrophicum" OR "atrophoderma pigmentosum" OR "melanosis lenticularis progressiva" OR "pigmented epitheliomatosis" OR "xeroderma of Kaposi" OR "xeroderma of the Kaposi" OR "xeroderma pigmentosum syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Xeroderma pigmentosum" OR "Kaposi dermatosis" OR "Kaposi disease" OR "angioma pigmentosum atrophicum" OR "atrophoderma pigmentosum" OR "melanosis lenticularis progressiva" OR "pigmented epitheliomatosis" OR "xeroderma of Kaposi" OR "xeroderma of the Kaposi" OR "xeroderma pigmentosum syndrome"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 6 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: XP
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T15:53:14.998Z
